Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hangzhou haorun technology co.,ltd. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - protection from the sun’s damaging effects.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ascend laboratories, llc - deferasirox (unii: v8g4mof2v9) (deferasirox - unii:v8g4mof2v9) - deferasirox oral granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. deferasirox oral granules is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (ntdt) syndromes and with a liver iron concentration (lic) of at least 5 milligrams of iron per gram of liver dry weight (mg fe/g dw) and a serum ferritin greater than 300 mcg/l. this indication is approved under accelerated approval based on a reduction of liver iron concentrations (to less than 5 mg fe/g dw) and serum ferritin levels [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. the safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. deferasirox is contraindicated in patients with: - estimated gf